Cervical cancer screening technology company, TruScreen Limited (NZAX: TRU) is pleased to announce the appointment of Mr John (Chris) Lawrence as a director to the TruScreen Board, effective from 21 December 2017.
Chris is a successful New Zealand businessman and a significant investor in life science and biotechnology businesses. He is a significant investor in Truscreen and was a major contributor to the March 2017 capital raising.
Chairman of TruScreen, Mr Robert Hunter, commented: “We are fortunate to have Mr Lawrence join the Board. His business experience and alignment with shareholder and company objectives will be of value as we progress our commercial strategy.”
Mr Lawrence is ordinarily resident in New Zealand and has been appointed by the current TruScreen directors, as permitted under TruScreen’s constitution. He will hold office until TruScreen’s 2018 Annual Meeting at which time he will offer himself for election by shareholders.